JACKSONVILLE, Fla.-08-18- 2008--Wearers of monthly replacement
contact lenses notice a decline in lens performance in the third and
fourth weeks of wear, a new survey sponsored by Johnson & Johnson
Vision Care indicates. Findings from the research--which surveyed
monthly CL wearers in France, with 20 different brands of lenses
represented--show a decrease in wearing comfort over the course of a
month, according to the company, with no significant differences
between wearers of Hydrogel and silicone Hydrogel monthly replacement
lenses. Seventy-one percent of monthly silicone Hydrogel CL wearers
and 68 percent of Hydrogel lens wearers reported a decrease in wearing
comfort as the month progressed, according to the survey. And 95
percent of respondents said they become aware of discomfort in weeks
three and four. Monthly silicone Hydrogel wearers who experienced
discomfort tended to notice it earlier in the lens cycle than Hydrogel
wearers. "The key to success with any patient centers around selecting
the appropriate lens, replacement frequency and wearing modality that
best fits his/her lifestyle needs," said Sheila Hickson-Curran,
director, medical affairs, for J&J Vision Care's Vistakon division.
"This study suggests that eye care practitioners should consider
questioning their monthly replacement CL wearers specifically on
whether comfort performance meets their needs in the third and fourth
weeks of wear." The survey also queried CL wearers about their
perceptions of the ECP's role in communicating the benefits of contact
lens innovations. Eighty-one percent said they expect their doctor to
recommend an upgrade on comfort grounds, and three quarters said they
would consider seeing their ECP more often if he or she would
proactively propose lenses that would give them better comfort. The
online survey was conducted last October and November. Data was
analyzed for 434 existing CL wearers who completed the survey; of
these, 271 were wearing monthly replacement Hydrogel lenses and 163
wore monthly silicone Hydrogel lenses.
- Monthly Replacement-CL
Wearers Face Decrease in Wearing Comfort Over Time
Purchase Contact Lenses Online Face Greater Eye
- New York NY, 01-13-2008 A
study reported in the January issue of Optometry: Journal of the
American Optometric Association, indicates that internet lens
purchasers typically don't follow their eye doctor's recommendations,
potentially placing them at greater risk for harmful eye care
practices and eye health complications. The research was conducted by
Joshua Fogel, Ph.D., and Chaya Zidile of Brooklyn College. The study
included 151 students from the university who were contact lens
The findings indicated that online and store purchasers
(consumers who get their contacts at a wholesale club or optical chain
outlet) are less likely to adhere to healthy eye care practices, as
recommended by their eye doctor. "We found that a pattern exists
regarding the method of contact lens purchasing and following
recommendations from the Food and Drug Administration (FDA)," said Dr.
Fogel. "Those who bought contact lenses at their doctor's office
followed a number of FDA recommendations more so than those who bought
contact lenses elsewhere."
The study, which researched the purchasing and eye care behaviors
of contact lens wearers, found that 86 percent of individuals who
purchased their lenses from an eye doctor received a yearly
comprehensive eye examination. But, only 76.5 percent of those
individuals who purchased their lenses via the Internet saw an eye
doctor on a routine basis. Also, despite potential uncomfortable side
effects, 35 percent of online purchasers did not check that the order
matched their prescription.
One of the largest discrepancies found between in-office and
out-of-office contact lens purchases was seen in the number of
individuals who saw an eye doctor for a follow-up appointment to
ensure the proper fit of their lenses. Fifty-seven percent of
individuals who purchased their lenses from an eye doctor went in for
a follow-up appointment, as compared to only 29 percent of online
(Thank you to Contact Lenses Today® and the staff of Contact
American Academy of Ophthalmology Warns
Consumers about Decorative Contacts
San Francisco CA,
The American Academy of Ophthalmology issued a reminder to consumers
that serious eye disorders can be caused by over-the-counter lenses.
In the statement the Academy noted that those most likely to buy
decorative contacts—teens and young adults—are also most likely to be
unaware of the risks these devices can pose to their eyes and
life-long visual health.
Although over-the-counter sales of nonprescription "plano"
cosmetic lenses have been illegal in the United States since 2005,
decorative contacts are still widely available in retail stores and on
the Internet. They are especially popular at Halloween as accessories
to costumes. Because consumers buying over-the-counter are not
educated on proper use and care of decorative contacts, they do not
realize the harm that can result from improper use.
The Academy suggested that consumers go to
www.geteyesmart.org, the Academy's public website for more
information about cosmetic lenses.
NAD Recommends Bausch & Lomb Discontinue Claims for
New York, NY.,
The National Advertising
Division (NAD) of the Council of Better Business Bureaus, one of the
investigative arms of the advertising industry’s voluntary
self-regulation program, has recommended that Bausch & Lomb, Inc.
discontinue claims that suggest that ReNu MultiPlus Solution is the
top-selling or most "trusted" among contact lens wearers. The
advertising claims made by B&L were challenged by Alcon Laboratories,
Inc., maker of Opti-Free Express.
Specifically, the following claims were challenged: "ReNu
MultiPlus Solution is a solution for soft contact lenses. It is the #1
selling Multi-purpose formula in the U.S." and ReNu MultiPlus "has
been trusted by over 20 million contact lens wearers and their eye
In its decision, NAD noted that it is undisputed that Alcon’s
Opti-Free Express is currently the leading selling manufacturer brand
of multi-purpose solution in the U.S. market, however, nothing in its
decision precludes B&L from making an expressly qualified claim that
the formula sold under the brand name ReNu MultiPlus together with the
same formula as private label store brands is the #1 selling contact
lens formula in the United States.
NAD also concluded that the evidence was not sufficient to
support the advertiser’s claim that ReNu MultiPlus "has been trusted
by over 20 million contact lens wearers and their eye care
Bausch and Lomb in its advertiser’s statement said that while it
is "disappointed by NAD’s finding that the selection and use by
consumers of a medical device does not equate with consumer trust of
the product, Bausch & Lomb will be guided by NAD’s recommendations in
its future advertising."
FDA Concerned Patients May Still be Using Complete MoisturePlus
- Washington, DC.,
08-05-2007 On August 1, the U.S Food and Drug Administration
(FDA) announced that many consumers might not be aware of the May 2007
recall of Advanced Medical Optics' (AMO) Complete MoisturePlus
multipurpose contact lens solution and continue to use the recalled
product. Following the recall announcement, it says several cases of
Acanthamoeba keratitis have been reported to the Centers for
Disease Control and Prevention (CDC) that involve use of the solution.
The agency said that individuals who wear soft contact lenses should
immediately stop using the product and discard all remaining solution,
including partially used or unopened bottles.
- AMO Recalls
Complete MoisturePlus MPS
New York, NY.,
Late Friday evening, Advanced
Medical Optics (AMO) announced an immediate voluntary recall of its
Complete MoisturePlus (CMP) multipurpose contact lens solution (MPS)
after data from the Centers for Disease Control (CDC) showed the risk
of developing Acanthamoeba keratitis (AK) was at least seven
times greater for patients who used AMO CMP. No single lot number was
repeated, suggesting that AMO CMP was not intrinsically contaminated.
In Jan. 2007, the CDC initiated a retrospective survey of 22
ophthalmology centers nationwide to assess whether cases of AK were
increasing in the U.S. In March 2007, data from 13 centers
demonstrated an increase in culture-confirmed cases of AK with wide
geographic distribution. On March 16, the CDC initiated a multi-state
investigation to look for risk factors associated with the increase in
AK cases. The report indicated an association with AK in soft contact
lens wearers who had used AMO CMP solution. The CDC has received
reports of 138 cases of culture-confirmed AK in 35 states and Puerto
Rico, with complete patient data available for 46 case-patients.
Lab testing is ongoing, but an initial analysis was conducted
using data from the first 46 completed patient interviews. Among the
46 culture-confirmed patients interviewed, 59% (27) were female, 85%
(39) wore soft contact lenses. In addition, 38% (16) reported swimming
and 83% (35) reported showering while wearing their contact lenses. Of
the 39 patients for whom clinical data was available, 36 reported
using one or more specific types of contact lens solution, 21 (58%)
reported some use of AMO CMP in the month before onset of symptoms, 20
(56%) reported using AMO CMP as their primary solution and 14 (39%)
reported using AMO CMP exclusively. The CDC notes that although the
results of the initial analysis are preliminary, they suggest that use
of AMO CMP increases the risk for AK.
B&L Suspends ReNu Shipments in U.S.
New York, NY.,
04-12-2006 Bausch & Lomb (B&L) voluntarily suspended
U.S. shipments of ReNu with MoistureLoc lens care solutions, following
an alert from the Centers for Disease Control (CDC) and Food and Drug
Administration yesterday. The alert concerns an increasing number of
Fusarium keratitis infections reported in the U.S. The CDC, FDA
and local health departments are involved in an ongoing investigation
to determine the source. As of April 9th, a total of 109 patients were
under investigation in Calif., Conn., Fla., Ga., Iowa, Md., Mass.,
Mich., Miss., N.J., N.Y., N.D., Ohio, Pa., Tenn., Texas and Vt.
Below you will find the link to the federal Department of Health and
Human Services CDC report:
The FDA says of the 30 cases investigated so far, 28 wore soft
contact lenses. In the contact lens group, 26 (93%) remembered which
solution they were using and all of them (100%) reported using a ReNu
brand solution or a generic equivalent manufactured by the company.
Five patients (18%) reported using other solutions in addition to
ReNu, including some manufactured by Advanced Medical Optics (AMO) and
Alcon. Nine admitted to wearing lenses overnight. However, no cause
has been established.
B&L is working closely with the CDC and the Wilmer Eye Institute
of Johns Hopkins University to implement a multi-center surveillance
program to establish the actual incidence. The company will also
change its recommendation for replacing lens cases from once every
three months to once per month, and stresses the importance of proper
lens cleaning and care.
The CDC advises clinicians who notice signs and symptoms of
keratitis to consider the possibility of infection and obtaining a
clinical specimen before initiating treatment. Report cases of
Fusarium keratitis to state and local departments or directly to
B & L Letter to Practitioners
AMO Letter to
- CooperVision and Ocular Sciences has
created the world's third-largest CL
- LAKE FOREST, Calif., 01-12-2005- The Jan. 6 closing of
CooperVision parent The Cooper Companies' $1.2 billion purchase of
fellow contact-lens manufacturer Ocular Sciences has created the
world's third-largest CL company, with combined revenues under the
CooperVision umbrella expected to top $755 million this year.
Completion of the transaction came one day after the Federal Trade
Commission finished its review of the deal Both companies'
stockholders approved the transaction Nov. 16.
In closing the acquisition, Cooper paid about $600 million in cash
and issued approximately 10.7 million shares of its common stock to
Ocular Sciences' stockholders and option holders.
"This acquisition is an ideal strategic fit for Cooper," said A.
Thomas Bender, Cooper's chief executive officer. "Ocular brings
geographic and product-line balance and manufacturing technology to
our Cooper Vision business unit. We expect to nearly double our
revenue base and enhance our cash flow and profitability."
The company said it now expects CooperVision's revenues to reach
$755 million to $765 million this fiscal year and $915 million to
$920 million in FY2006. In fiscal 2004, which ended Oct. 31,
CooperVision's revenues were $388.7 million.
Ocular Sciences has not yet reported its fiscal 2004 revenues;
through its third quarter ended Sept. 30, Ocular's total sales were
"Combining Cooper and Ocular Sciences is a strategic opportunity
that immediately creates a company with significant scale and
presence in all major markets around the world," said John Fruth,
Ocular Sciences' founder and chairman, who joined Cooper's board of
directors. "The combined companies will offer our customers a wider
choice of contact lens products for their patients."
"We firmly believe that the integration of these businesses will
help CooperVision better fulfill our promise to provide eye care
practitioners with the highest levels of service, as well as product
quality, reliability, and delivery," agreed Greg Fryling, chief
operating officer of CooperVision.
Throughout the transition, CooperVision will continue to conduct
business as usual, and will work to ensure that practitioners
experience minimal changes and disruptions in service, ordering, or
product availability, the company said.
The acquisition brings two companies with complementary product
lines under a single umbrella. Bender said Ocular offers
disposable-spheric and daily-disposable contact lenses. while
Cooper's emphasis is specialty lenses such as Multifocals, dry eye,
and cosmetic CLs. In addition, he said Ocular has traditionally been
strong with U.S. retail optical chains. While, Cooper's distribution
focuses on independent eyecare professionals. The deal also offer;
global distribution synergies.
Vision Shaping Treatment Approved by
ROCHESTER, N.Y., 01-10-2005 Bausch & Lomb has
received FDA approval for an enhanced fitting guide for its Vision
Shaping Treatment (VST), a temporarily reshape the cornea to correct
up to -5.00D of myopia and low amounts of astigmatism. (VST) uses
B&L's patented Boston Equalens II brand GP lens material in four
different lens designs. This vision correction method that uses
custom-fit GP contact lenses worn overnight to method has been
available in Canada for several years.
An online orthokeratology certification program is available via
B&L's practitioner Web site. After reviewing the Orthokeratology
Interactive Educational Program, practitioners can go to the
certification module to test their knowledge of the program.
Practitioners who score 75 percent or higher will receive a
B&L Sues Ocular Sciences, Charging Patent
Infringement on Toric CLs
- ROCHESTER, N.Y.-Bausch & Lomb (B&L) filed suit
against Ocular Sciences in U.S. District Court for the Western
District of New York here on October 5, charging patient infringement.
The suit relates to Ocular's Biomedics toric soft contact lens and its
private-label equivalent, used to correct astigmatism.
Bausch & Lomb's suit charged that the Ocular lenses infringe on the patent for
Bausch & Lomb's SofLens66 Toric CL.
In its suit, B&L asked the court for injunctive relief to require
Ocular to discontinue manufacturing
and sales in the U.S. of its allegedly infringing toric lens until the
Bausch & Lomb patent expires in 2018, plus unspecified monetary damages.
"We believe this lawsuit is without merit, and we plan to conduct a
vigorous defense," said Stephen Fanning, Ocular's president and chief
executive officer. "We have been in discussion with Bausch & Lomb on
this matter since January 2004, have investigated the matter in detail,
and believe that our patented Biomedics toric soft CL and the
private-label equivalent do not infringe the B&L patent."
Sciences merge for a New Contact-Lens Power
- CONCORD, Calif., 08-16-2004 When the Cooper Companies, parent of
contact-lens manufacturer CooperVision, completes its acquisition of
CL competitor Ocular Sciences late this year or early in 2005,
CooperVision will immediately take over third position in the global
contact lens business, the company said.
- The deal, valued at approximately $1.2 billion, is expected to
close in the first quarter of Cooper's 2005 fiscal year, which
begins Nov. 1. At closing, Cooper will pay approximately $600
million in cash and issue approximately 10.3 million shares of its
common stock to Ocular Sciences' stockholders and option holders.
- CooperVision, which ranks itself as the world's fourth largest
contact lens manufacturer, has estimated fiscal 2004 revenues of
about $385 million. Ocular Sciences, said to be the world's
fifth-largest CL maker, expects revenues of about $345 million for
- As a result of their merger, CooperVision and Ocular will be
able to "compete global market with a full line of produces," Cooper
Companies chairman Thomas Bender said last month.
- Bender said Ocular is strong with retail optical chains, while
Cooper's distribution focuses on independent eyecare professionals.
Also, Ocular offers disposable spheric and daily-disposable contact
lenses, while Cooper specializes in specialty lenses such as
multifocal, dry-eye, and cosmetic CLs. "And the cultures of the two
companies mesh very well," Bender added. Some consolidation of the
two companies' operations can be expected, he acknowledged, "but the
main manufacturing planes will not be affected."
- Added John Fruth, Ocular's chairman, "Today optical chains are
looking to consolidate their number of providers, so by adding
additional produces [to the two companies' combined product line] we
become more of a one-stop shop for them."
- Fruth will join Cooper's board as a director once the deal
closes, according to Bender.
- This will be Cooper's second major acquisition in less than
three years; the company purchased CL manufacturer Biocompatible in
- 1-800-Contacts Files Legal Action Against
- DRAPER, Utah., 03-22-2004 1-800-CONTACTS filed legal action
today in the United States Federal Court for the District of Utah
against Coastal Contacts for trademark infringement, unfair
competition, trademark dilution, copyright infringement, unfair
trade practices and other related claims. The company does not
believe the legal costs related to this action will have a material
impact on its financial results.
- Bausch & Lomb
and CIBA Vision reached a final settlement
- ROCHESTER, N.Y.
, 08-01-2004 Bausch & Lomb (B&L) and
CIBA Vision, the eyecare unit of Novartis,
reached a final settlement last month resolving long-standing disputes
between the two companies in patent infringement lawsuits related to silicone hydrogel
Under the new agreement, B&L and CIBA have agreed to cross-license rights
to their silicone hydrogel CL technologies. B&L will pay CIBA Vision a royalty on U.S. sales of its
PureVision lenses until 2014, and on sales outside the U.S. until 2016.
The 30-day extended-wear PureVision CLs have been off the market in the
U.S. since June 2002 because of the patent dispute. Following a ruling at that time, B&L transferred
manufacturing and shipping of its PureVision lenses to its facility in Waterford, Ireland, and continued to
sell the CLs outside the U.S. from there.
The pact between the two firms resolves patent lawsuits in U.S. district
courts in Georgia, Delaware, and New York, as well as other suits and patent proceedings in Germany,
Ireland, the European Patent Office, and Australia.
B&L can resume U.S. sales and manufacture of Pure Vision CLs on April 27,
2005, upon expiration of the patent that was the subject of a 2002 ruling in the Federal district court in
Delaware; its Pure Vision lenses will continue to be available outside the U.S. CIBA Vision's Focus Night & Day
CLs continue to be available worldwide.
"While the process that led to this settlement was a long one, both CIBA
Vision and Bausch & Lomb believe the settlement is in the best interests of eye care professionals and
consumers around the world," said Andrea Saia, president of CIBA Vision's global lens business.
Added Angela Panzarella, B&L's corporate vice president-global vision
care, "This agreement allows us to focus our efforts on expanding our strong market position and continue
development of new advances in silicone hydrogel materials."